1 The retractions came only weeks after BioMed Central.

An editor at one of the journals published by Sage Publications became suspicious, sparking an extended and comprehensive investigation, which led to the retraction of 60 articles in July 2014. By the end of 2014, BioMed Central and other publishers alerted the international Committee on Publication Ethics to new types of systematic attempts to control journals’ peer-review processes. According to a declaration published on COPE’s internet site in January 2015, these attempts to hijack the scholarly review program were evidently orchestrated by firms that first helped authors compose or improve their scientific articles and offered them favorable peer evaluations.4 BioMed Central conducted a thorough investigation of most their recently published content and identified 43 that were published on the basis of reviews from fabricated reviewers.Published results for ANAVEX 1-41, ANAVEX 2-73 and ANAVEX 7-1037 are available at Corporate Advancements On the corporate front in 2007, Dr. Panos Kontzalis was appointed as CEO and Director, Dr. Alexandre Vamvakides became Chief Scientific Officer and Director, and ANAVEX added a distinguished, qualified MBA to its Board of Directors medically. The business attracted prominent researchers Dr. Jean Jacques Dr and Bourguignon. Tangui Nicolas Maurice, who joined the business’s scientific team and were appointed as users of the scientific committee. Dr. Kontzalis is definitely a 38-yr pharmaceutical-sector veteran. He offers held several senior positions at Novartis Pharma in Basel, Switzerland, including Market and Business Analyst for the central nervous system portfolio, Group Marketplace and Business Analyst for the transplantation, dermatology, rheumatology and cardiovascular portfolio, and Market Research and Competitive Intelligence Manager for transplantation, oncology and immunology.